A small study presented at the European Association for the Study of Diabetes meeting revealed severely obese type 2 diabetes patients who used EndoBarrier, a duodenal-jejunal bypass liner, showed reduced HbA1C levels, dropping from 8.5% to 7.5% at one year. In addition, patients reduced their body weight by an average of 10% and experienced improvements in fasting glucose levels and systolic blood pressure.

Related Summaries